Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Stephen C BainEllen BurgessPriya VartGlenn M ChertowFan Fan HouNiels JongsJohn Joseph Valentine McMurrayRicardo Correa-RotterHarpreet S BajajBergur V StefanssonRobert D TotoAnna Maria LangkildeDavid C WheelerHiddo J Lambers Heerspinknull nullPublished in: Diabetes care (2021)
Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.